A new global Phase III trial, AFT-70 NAVIGATE, will test whether ultrasensitive Signatera blood MRD monitoring can help spare early breast cancer patients from toxicity by guiding the use of CDK4/6 inhibitors. The design evaluates escalation of therapy based on molecular residual disease detection in ER-positive/HER2-negative settings, combining giredestrant with MRD-guided decisions.